secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2024-11-21T23:59:59+00:00
Accession:  0001193125-24-262940
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz Pharmaceuticals receives FDA accelerated approval for Ziihera in HER2+ biliary tract cancer
--------------------------------------------------------------------------------

- FDA approved Ziihera (zanidatamab-hrii) for adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) BTC.
- Approval based on 52% objective response rate and median duration of response of 14.9 months by independent central review.
- First and only dual HER2-targeted bispecific antibody approved for this indication in the U.S.
- Continued approval contingent on confirmatory Phase 3 trial HERIZON-BTC-302; Boxed Warning for embryo-fetal toxicity.
- Investor webcast scheduled for December 11, 2024, to discuss clinical data and commercialization strategy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000119312524262940/0001193125-24-262940-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000119312524262940/d832756d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-262940

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer